Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

275 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Donor type, in addition to transplantation in chronic phase and myeloablative conditioning, influence transplant survival for patients with advanced chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Kongtim P, Adekola K, Milton DR, Ramlal R, Jimenez A, Chen J, Rondon G, Ahmed S, Kebriaei P, Betul O, Hosing CM, Popat U, Khouri I, Jabbour E, Cortes JE, Kantarjian HM, Champlin RE, Ciurea SO. Kongtim P, et al. Among authors: khouri i. Leukemia. 2017 Jul;31(7):1654-1657. doi: 10.1038/leu.2017.118. Epub 2017 Apr 12. Leukemia. 2017. PMID: 28400618 Free PMC article. No abstract available.
Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: khouri i. Leuk Lymphoma. 2019 Dec;60(14):3536-3543. doi: 10.1080/10428194.2019.1633633. Epub 2019 Jul 8. Leuk Lymphoma. 2019. PMID: 31282244
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
de Lima M, Champlin RE, Thall PF, Wang X, Martin TG 3rd, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. de Lima M, et al. Among authors: khouri i. Leukemia. 2008 Feb;22(2):258-64. doi: 10.1038/sj.leu.2405014. Epub 2007 Nov 8. Leukemia. 2008. PMID: 17989720 Clinical Trial.
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK, Saliba RM, Rondon G, Ahmed S, Alousi A, Bashir Q, Ciurea SO, Popat U, Khouri I, Marin D, Rezvani K, Kebriaei P, Shpall EJ, Champlin RE, Oran B. Yucel OK, et al. Among authors: khouri i. Cancer. 2017 Jul 15;123(14):2661-2670. doi: 10.1002/cncr.30632. Epub 2017 Mar 21. Cancer. 2017. PMID: 28324640 Free article.
Allogeneic haematopoietic transplantation for Richter's syndrome.
Rodriguez J, Keating MJ, O'Brien S, Champlin RE, Khouri IF. Rodriguez J, et al. Among authors: khouri if. Br J Haematol. 2000 Sep;110(4):897-9. doi: 10.1046/j.1365-2141.2000.02295.x. Br J Haematol. 2000. PMID: 11054078 Free article.
275 results